tradingkey.logo
搜索

Pacific Biosciences of California Inc

PACB
添加自选
1.395USD
+0.015+1.09%
收盘 07-23 16:00美东报价延迟15分钟
433.13M总市值
亏损市盈率 TTM

Pacific Biosciences of California Inc

1.395
+0.015+1.09%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+1.09%

5天

-6.38%

1月

+6.49%

6月

-45.93%

今年开始到现在

-25.40%

1年

-17.46%

关键数据
1.360今开
1.430最高
6.86M成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
2.21%换手率
1.380昨收
1.360最低
7.58M成交额
亏损市盈率静
183.06市净率
0.00%股息率 TTM
-15.65%ROA
2.73052周最高
0.92量比
-309.85M净利润
310.49M总股本
-0.4133每股收益TTM
2.36Beta
-273.55%ROE
0.96052周最低
5.07%振幅
32.30%毛利率
433.13M总市值
-0.82回报/风险
5.08%风险率

操作建议

Pacific Biosciences of California Inc当前公司基本面数据相对谨慎,增长潜力较大。当前估值合理,在医疗设备与耗材行业排名108/200位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价2.46。中期看,股价处于下降通道。近一个月,市场表现较差,基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间,可以做区间波段操作。

Pacific Biosciences of California Inc评分

相关信息

行业排名
108 / 200
全市场排名
211 / 4547
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
看空

Pacific Biosciences of California Inc亮点

亮点风险
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
利润高增长
公司净利润处于行业前列,最新年度总收入160.00M美元
估值低估
公司最新PE估值-3.39,处于3年历史低位
机构减仓
最新机构持股192.85M股,环比减少9.18%
凯茜·伍德(木头姐)持仓
明星投资者凯茜·伍德(木头姐)持仓,最新持仓市值37.12M

分析师目标

根据 8 位分析师
买入
评级
2.458
目标均价
+75.59%
涨幅空间

Pacific Biosciences of California Inc新闻

即将为您带来更多新闻,敬请期待。。。

收益预测

分析师评级

根据 8 位分析师
买入
评级
2.458
目标均价
+75.59%
涨幅空间
强力买入
买入
持有
卖出
强力卖出

同行比较

88
总数
4
中位数
7
平均值
公司名称
评级分布
分析师数
Pacific Biosciences of California Inc
PACB
8
波士顿科学
BSX
37
直觉外科
ISRG
35
Edwards Lifesciences Corp
EW
33
Veeva Systems Inc
VEEV
30
赛默飞世尔科技
TMO
30
1
2
3
...
18

技术指标

技术指标
卖出(1)
中性(4)
买入(1)
指标
数值
方向
MACD(12,26,9)
-0.053
中性
RSI(14)
44.107
中性
STOCH(KDJ)(9,3,3)
21.469
中性
ATR(14)
0.094
低波动
CCI(14)
-95.582
中性
Williams %R
83.117
超卖
TRIX(12,20)
-0.079
卖出
StochRSI(14)
76.997
买入
移动平均线
卖出(6)
中性(0)
买入(0)
指标
数值
方向
MA5
1.396
卖出
MA10
1.455
卖出
MA20
1.548
卖出
MA50
1.428
卖出
MA100
1.449
卖出
MA200
1.711
卖出

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Pacific Biosciences of California Inc简介

Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
公司代码PACB
公司Pacific Biosciences of California Inc
CEOHenry (Christian O)
网址https://www.pacb.com/

公司股东

持股股东
持股股东
占比
ARK Investment Management LLC
11.68%
SoftBank Group Corp
6.58%
BlackRock Institutional Trust Company, N.A.
6.53%
Vanguard Capital Management, LLC
4.11%
Geode Capital Management, L.L.C.
2.28%
其他
68.81%

常见问题

Pacific Biosciences of California Inc(PACB)的当前股价是多少?

Pacific Biosciences of California Inc(PACB)的当前股价是 1.40。

Pacific Biosciences of California Inc的股票代码是什么?

Pacific Biosciences of California Inc的股票代码是PACB。

Pacific Biosciences of California Inc股票的52周最高点是多少?

Pacific Biosciences of California Inc股票的52周最高点是2.73。

Pacific Biosciences of California Inc股票的52周最低点是多少?

Pacific Biosciences of California Inc股票的52周最低点是0.96。

Pacific Biosciences of California Inc的市值是多少?

Pacific Biosciences of California Inc的市值是433.13M。

现在Pacific Biosciences of California Inc(PACB)的股票是买入、持有还是卖出?

根据分析师评级,Pacific Biosciences of California Inc(PACB)的总体评级为买入,目标价格为2.46。

Pacific Biosciences of California Inc(PACB)股票的每股收益(EPS TTM)是多少

Pacific Biosciences of California Inc(PACB)股票的每股收益(EPS TTM)是-1.82。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有